[1]林子健,曹小冬.天冬酰胺类抗体-药物偶联物连接子的合成新工艺[J].浙江理工大学学报,2023,49-50(自科五):612-617.
　LIN Zijian,CAO Xiaodong.A novel synthetic technology of asparagine  antibody drug conjugate linker[J].Journal of Zhejiang Sci-Tech University,2023,49-50(自科五):612-617.

点击复制

天冬酰胺类抗体-药物偶联物连接子的合成新工艺()

分享到：

参考文献/References:

［ 1 ］ Beck A, Haeuw J F, Wurch T, et al. The next generation of antibody-drug conjugates comes of age［J］. Discovery Medicine, 2010, 10(53): 329-339.

［2］Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies［J］. CA: A Cancer Journal for Clinicians, 2022, 72(2): 165-182.

［3］Fu Z W, Li S J, Han S F, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy［J］. Signal Transduction and Targeted Therapy, 2022, 7(4): 1066-1090.

［4］Salomon P L, Singh R. Sensitive ELISA method for the measurement of catabolites of antibody-drug conjugates (ADCs) in target cancer cells［J］. Molecular Pharmaceutics, 2015, 12(6): 1752-1761.

［5］Whiteman K R, Johnson H A, Sun X X, et al. Anti-tumor activity and pharmacokinetics of the anti-FOLR1-maytansinoid conjugate IMGN853 is maintained over a wide range of maytansinoid to antibody ratios［J］. Cancer Research, 2012, 72(8): 4628-4628.

［6］Moore K N, Martin L P, O’Malley D M, et al. Safety and activity of mirvetuximab soravtansine (IMGN 853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2017, 35(10): 1112-1118.

［7］Chen H, Liu X, Clayman E S, et al. Synthesis and evaluation of a CBZ-AAN-Dox prodrug and its in vitro effects on SiHa cervical cancer cells under hypoxic conditions［J］. Chemical Biology & Drug Design, 2015, 86(4): 589-598.

［8］Okeley N M, Miyamoto J B, Zhang X, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug ConjugateReleased Drug from SGN-35［J］. Clinical Cancer Research, 2010, 16(3): 888-897.

［9］Miller J T, Vitro C N, Fang S T, et al. Enzyme-agnostic lysosomal screen identifies new legumain-cleavable ADC linkers［J］. Bioconjugate Chemistry, 2021, 32(4): 842-858.

［10］Lerchen H G, Stelte-Ludwig B, Sommer A, et al. Tailored linker chemistries for the efficient and selective activation of ADCs with KSPi payloads［J］. Bioconjugate Chemistry, 2020, 31(8): 1893-1898.

相似文献/References:

[1]杨丽萍,曹小冬.2-磺酸-4-硫代丁酸类抗体-药物偶联物连接子的合成[J].浙江理工大学学报,2023,49-50(自科三):374.
　YANG Liping,CAO Xiaodong.Synthesis of 2-sulfonic acid-4-thiobutanoic acid antibody drug conjugate linker[J].Journal of Zhejiang Sci-Tech University,2023,49-50(自科五):374.